source
- Takeda drops its second celiac disease candidate, TAK-101, after unimpressive phase 2 resultsTakeda said it is halting development of TAK-101, its second candidate for celiac disease, after a phase 2 study failed to meet expectations. TAK-101 is a nanoparticle that carries gliadin, a glut…
- GSK signs up to $110 million AI data partnership with RelationGSK announced a research collaboration with AI-focused biotech Relation, valued at up to $110 million. Under the agreement Relation will produce large-scale datasets that capture how human cells r…